Significance of serum carcinoembryonic antigen in metastatic breast cancer patients: A prospective study

Figure 1 Receiver operator characteristic curves. A: Pre-treatment receiver operator characteristic (ROC) curve for whole study population; B: Pre-treatment ROC curve for luminal type; C: Post-treatment ROC curve for whole study population; D: Post-treatment ROC curve for luminal type. ROC: Receiver operator characteristic; CEA: Carcinoembryonic antigen.

Figure 2 Treatment response. A: Association of treatment response with serum carcinoembryonic antigen (CEA) (pre-treatment and post-treatment) in whole study population; B: Association of treatment response with serum CEA in non-luminal type; C: Association of treatment response with serum CEA in luminal type. CEA: Carcinoembryonic antigen.

Figure 3 Median pre-treatment and post-treatment serum carcinoembryonic antigen levels in responders and non-responders according to various sites of metastasis. A: Median pre-treatment serum carcinoembryonic antigen (CEA) level; B: Median post-treatment serum CEA level. CEA: Carcinoembryonic antigen.

Figure 4 Association of post-treatment serum carcinoembryonic antigen with bone metastases. CEA: Carcinoembryonic antigen.